Cancer Research UK: DETERMINE (Determining Extended Therapeutic indications for Existing drugs in Rare Molecularly defined Indications using a National Evaluation platform trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers with Actionable Genomic Alterations, including Common Cancers with Rare Actionable Alterations. More info here.

Day One Biopharmaceuticals: FIRELIGHT-1 A (Phase 1b/2): Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations. 2023.

ELI LILLY AND COMPANY: LIBRETTO-531 (Phase III): ‘A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)’. 2021.

ELI LILLY/LOXO ONCOLOGY: LIBRETTO-001 (Phase I –II): ‘A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)’. 2021.

Roche: TAPISTRY (Phase II): ‘Tumor-agnostic precision immuno-oncology and somatic targeting rational for you (TAPISTRY) phase II platform trial’. 2021.